We just came across one of the most outlandish claims since Technical420’s foray into covering the cannabis industry today and had to provide an update on it.

When investors think of the bellwether company in the biotech levered to the cannabis industry, the first name that comes to mind is GW Pharmaceutical (GWPH). The company has by far, the largest and most advanced pipeline of products in advanced stages of FDA testing.

One company that does not come to mind is AXIM Biotechnologies (AXIM).

This morning, AXIM was reported to have the broadest pipeline in the cannabis industry. This statement is completely misleading due to the fact that they refuse to disclose the amount of capital they raised in 2016 when they “raised enough capital to support the cost of clinical trials”. The article stated, “AXIM Biotech has developed one of the industry’s most diverse clinical pipelines with nine clinical programs in development (several have been recently added).

Per its website, the company plans to "launch the first of its pharmaceutical products by 2018/2019 with Phase IIA clinical data expected this year and next year.”

Read the rest of the article